Twelve month follow-up of the SWEN randomized controlled trials: Differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count
Post Date:
2011-03-27
Clinical Sites:
Publication:
AIDS Care
Summary:
Objectives: We previously reported combined analysis of 6-week and 6-month endpoints of three randomized controlled trials [Six Week Extended Dose Nevirapine (SWEN) trials] that compared extended-dose nevirapine through 6 weeks of age to single-dose nevirapine to prevent HIV transmission via breastfeeding and mortality. We now present endpoints through 12 months of age.
Design: Infants in Ethiopia, India, and Uganda born to HIV-infected women who chose to breastfeed were randomized to receive single-dose or extended-dose nevirapine.
Citation:
Omer S, for the Six Week Extended Dose Nevirapine (SWEN) Study Team. Twelve month follow-up of the SWEN randomized controlled trials: Differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count. AIDS Care. 2011 Mar 27; 25:767-776.
Read More: